Iovance Biotherapeutics (IOVA) Stock Overview
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IOVA Community Fair Values
Create NarrativeSee what 137 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5362.9% undervalued intrinsic discount
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeIovance Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.40 |
| 52 Week High | US$5.63 |
| 52 Week Low | US$1.64 |
| Beta | 0.76 |
| 1 Month Change | -0.87% |
| 3 Month Change | 28.79% |
| 1 Year Change | -2.86% |
| 3 Year Change | -51.98% |
| 5 Year Change | -87.18% |
| Change since IPO | -34.72% |
Recent News & Updates
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Narrative Update: Iovance Biotherapeutics The analyst price target for Iovance Biotherapeutics has been lifted to $4. This reflects updated models that incorporate Q4 fundamentals, margin progress and expectations around Amtagvi and broader trial momentum, while still acknowledging areas of uncertainty highlighted by recent Street research.IOVA: Q4 Margin Gains And Sarcoma Data Are Expected To Drive Upside
The average analyst price target for Iovance Biotherapeutics has moved higher toward $4, supported by research citing improved Q4 fundamentals, margin progress, and early signs that initial launch issues may be easing. Analyst Commentary Recent research highlights a mix of optimism around product execution and margins alongside pockets of caution on valuation and growth risks.Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Apr 07
IOVA: Margin Progress And 2026 Sarcoma Data Outlook Will Support Higher Future P/E
The analyst fair value estimate for Iovance Biotherapeutics has been adjusted from $17.00 to $16.00, reflecting updated views on revenue growth, margins, and future P/E assumptions as analysts respond to recent price target moves and Q4 results across the Street. Analyst Commentary Street research around the latest quarter points to a generally constructive shift in sentiment, with several bullish analysts lifting price targets and, in one case, upgrading the rating on Iovance Biotherapeutics.Recent updates
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Narrative Update: Iovance Biotherapeutics The analyst price target for Iovance Biotherapeutics has been lifted to $4. This reflects updated models that incorporate Q4 fundamentals, margin progress and expectations around Amtagvi and broader trial momentum, while still acknowledging areas of uncertainty highlighted by recent Street research.IOVA: Q4 Margin Gains And Sarcoma Data Are Expected To Drive Upside
The average analyst price target for Iovance Biotherapeutics has moved higher toward $4, supported by research citing improved Q4 fundamentals, margin progress, and early signs that initial launch issues may be easing. Analyst Commentary Recent research highlights a mix of optimism around product execution and margins alongside pockets of caution on valuation and growth risks.Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Apr 07IOVA: Margin Progress And 2026 Sarcoma Data Outlook Will Support Higher Future P/E
The analyst fair value estimate for Iovance Biotherapeutics has been adjusted from $17.00 to $16.00, reflecting updated views on revenue growth, margins, and future P/E assumptions as analysts respond to recent price target moves and Q4 results across the Street. Analyst Commentary Street research around the latest quarter points to a generally constructive shift in sentiment, with several bullish analysts lifting price targets and, in one case, upgrading the rating on Iovance Biotherapeutics.IOVA: Fair Outlook Balances Q4 Progress With 2026 Clinical And Launch Risks
The analyst price target for Iovance Biotherapeutics has shifted from $2 to $4 as analysts point to stronger Q4 fundamentals, improving margins, ongoing manufacturing progress, and early signs that some initial launch issues for Amtagvi may be easing, even while longer term revenue acceleration remains uncertain. Analyst Commentary Recent Street research around Iovance Biotherapeutics reflects a mixed setup, with price target changes clustered across a wide range and ratings spanning Neutral to Buy.IOVA: Elevated Future P/E Will Likely Clash With 2026 Clinical Data Risks
Analysts have lifted their price targets on Iovance Biotherapeutics from a range starting at $3 to as high as $16, citing Q4 revenue momentum, improving gross margins and manufacturing efficiency, and expectations for more clinical data in 2026. Analyst Commentary Recent research highlights a split in how Wall Street views Iovance Biotherapeutics, with some firms lifting price targets on the back of Q4 execution and others trimming expectations while still acknowledging operational progress.IOVA: Elevated Future P/E Will Likely Expose Execution Risk
Analysts have raised their price target on Iovance Biotherapeutics by $0.50, citing updated assumptions around fair value, growth, margins, and future P/E that reflect recent Street research. Analyst Commentary Recent Street research on Iovance Biotherapeutics has highlighted a mix of optimism and caution around the updated price target, with some readers likely to focus less on the small US$0.50 change and more on what it implies about risk and execution.IOVA: Reaffirmed 2025 Revenue Outlook Will Support A Higher Future P/E
Analysts have trimmed their fair value estimate for Iovance Biotherapeutics from US$20.00 to US$17.00, citing updated assumptions that include a slightly higher discount rate, a lower projected revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the expected range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Key Developments).
IOVA: Lung Cancer Trial Progress Will Drive Bullish Repricing Ahead
Analysts have kept their price target for Iovance Biotherapeutics steady at US$8.35, citing only minor tweaks to inputs such as the discount rate and long term P/E assumptions rather than any fundamental shift in their outlook. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Company guidance).IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly increased their price target on Iovance Biotherapeutics by 0.10 dollars to reflect slightly lower perceived risk, as seen in a reduced discount rate, while maintaining robust long term revenue growth and profit margin expectations alongside a marginally higher future price to earnings multiple. What's in the News Iovance reaffirmed its full year 2025 revenue guidance of 250 to 300 million dollars for the first full calendar year of Amtagvi sales, signaling confidence in launch momentum (company guidance) Interim data from the registrational Phase 2 IOV-LUN-202 trial showed a 25.6 percent objective response rate for lifileucel monotherapy in previously treated advanced nonsquamous NSCLC without actionable mutations, including 2 complete and 7 partial responses and a 71.8 percent disease control rate (company trial update) The median duration of response for lifileucel in IOV-LUN-202 has not yet been reached after a median follow up of 25.4 months, indicating durable benefit among responding NSCLC patients (company trial update) Valuation Changes Fair Value: increased slightly from 8.25 dollars to 8.35 dollars, reflecting a modest uplift in the intrinsic valuation estimate.IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly reduced their price target on Iovance Biotherapeutics to reflect slightly slower projected revenue growth, a meaningfully lower long term profit margin outlook, and a higher assumed future price to earnings multiple, while leaving the estimated fair value effectively unchanged at about 8.25 dollars per share. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, targeting between 250 million dollars and 300 million dollars in the first full calendar year of Amtagvi sales (company guidance).IOVA: Future Phase 2 Data Will Drive Renewed Bullish Momentum
Analysts have raised their price target for Iovance Biotherapeutics from $7.75 to $8.25 per share, citing updated financial metrics and modestly adjusted long-term growth assumptions. What's in the News Iovance Biotherapeutics reaffirmed its revenue guidance for the full year 2025, projecting $250 to $300 million in the first full calendar year of Amtagvi sales.IOVA: Future Profitability Outlook Will Drive Renewed Investor Interest
Analysts have adjusted their price target for Iovance Biotherapeutics from $8.00 to $7.75. This change reflects updated views on the company's growth trajectory and profitability outlook.Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results
Nov 08
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
Analysts have lowered their price target for Iovance Biotherapeutics from $9.10 to $8.00. They cite updated expectations for slower revenue growth, compressed profit margins, and a higher required rate of return.Oncology Expansion And Global Approvals Will Unlock Future Markets
The consensus analyst price target for Iovance Biotherapeutics has been revised downward to $9.10 as slower-than-expected Amtagvi commercial adoption and logistical challenges outweigh positive early clinical response data. Analyst Commentary Bearish analysts cite a slower-than-expected commercial launch for Amtagvi in second-line melanoma, driving down sentiment and price targets.Oncology Expansion And Global Approvals Will Unlock Future Markets
The decrease in Iovance Biotherapeutics' consensus price target is primarily driven by a reduction in expected annual revenue growth from 49.7% to 45.5%, resulting in a lowered fair value estimate from $10.00 to $9.10. What's in the News Five-year results from the Phase 2 C-144-01 trial showed Amtagvi (lifileucel) produced a median OS of 13.9 months and a 31.4% objective response rate in advanced melanoma patients; 19.7% survived at five years with durable responses and no new safety concerns.Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth
Jul 22Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues
May 16News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat
May 13
US Launch And Global Expansion Will Create New Opportunities
The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.Iovance Biotherapeutics: Only For The Brave
Apr 22Iovance: The Company Makes It Hard To Estimate Revenue Growth
Mar 18Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Feb 28Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Jan 11Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
Dec 17Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Nov 11Iovance Biotherapeutics: Moving To The Next Phase
Oct 03Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Shareholder Returns
| IOVA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.9% | -1.7% | 0.9% |
| 1Y | -2.9% | 27.7% | 28.2% |
Return vs Industry: IOVA underperformed the US Biotechs industry which returned 27.7% over the past year.
Return vs Market: IOVA underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| IOVA volatility | |
|---|---|
| IOVA Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IOVA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IOVA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 975 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
Iovance Biotherapeutics, Inc. Fundamentals Summary
| IOVA fundamental statistics | |
|---|---|
| Market cap | US$1.40b |
| Earnings (TTM) | -US$390.98m |
| Revenue (TTM) | US$263.50m |
5.3x
P/S Ratio-3.6x
P/E RatioIs IOVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IOVA income statement (TTM) | |
|---|---|
| Revenue | US$263.50m |
| Cost of Revenue | US$173.18m |
| Gross Profit | US$90.32m |
| Other Expenses | US$481.30m |
| Earnings | -US$390.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 34.28% |
| Net Profit Margin | -148.38% |
| Debt/Equity Ratio | 0.1% |
How did IOVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 22:04 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iovance Biotherapeutics, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |